A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Short Half-Life and Rapid Clearance

An active that clears in minutes needs frequent dosing or a way to stay in circulation longer. Short half-life is why native GLP-1 was never a drug, and why half-life extension turned incretin analogs into once-weekly medicines.

Why compounds clear fast

Small peptides and hydrophilic molecules under about 60 kDa are filtered by the kidneys. Plasma enzymes such as DPP-4 cleave peptides, and hepatic metabolism removes lipophilic small molecules. Native GLP-1 lasts about 2 minutes; melatonin about 40 to 60 minutes; NAC around 6 hours for total drug. Short half-life produces sharp peaks and troughs, which can mean side effects at the peak and no activity at the trough. Clearance route decides which extension strategy can work.

Half-life extension strategies

Chemical strategies include PEGylation, fusion to albumin or Fc fragments, and fatty acid acylation that promotes reversible albumin binding. Semaglutide combines acylation and a DPP-4 resistant substitution to reach a half-life of about one week. Formulation strategies include depot injections, in situ gels, microspheres and controlled-release oral forms. Formulation cannot slow elimination once a molecule is free in plasma; it can only extend the input. The distinction matters when reading claims about long-acting formats.

Where controlled release helps

For supplements and oral small molecules, extended release smooths plasma levels, lowers peak concentrations and can reduce dose frequency. Melatonin is authorized in prolonged-release form in the EU and elsewhere for exactly this reason, because the immediate-release form clears within about an hour. Controlled release is also central to long-acting injectables developed by pharmaceutical partners, where the goal is fewer administrations. The same principle applies to oral nutrients with short plasma residence.

Key facts

Native GLP-1 has a half-life of about 2 minutes due to DPP-4 degradation (Deacon et al. 1995, Diabetes)
Semaglutide has an elimination half-life of about one week, supporting once-weekly dosing (FDA label, Ozempic 2017)
PEGylation extends circulating half-life by increasing hydrodynamic size and reducing renal clearance (Harris and Chess 2003, Nat Rev Drug Discov)
Prolonged-release melatonin 2 mg is authorized in the EU as Circadin (EMA, Circadin EPAR 2007)

How our delivery technology applies

Our layers extend the input phase, not the elimination phase. Stacked layers with different erosion rates release an active in stages, producing a longer, flatter absorption profile from one dose. That is useful for short half-life small molecules taken orally or topically. It does not substitute for chemical half-life extension of injected peptides, and we do not claim otherwise.

Discuss a controlled-release profile for your active.